logo

Halozyme Therapeutics, Inc. (HALO)



Trade HALO now with
  Date
  Headline
8/15/2022 10:51:42 PM Halozyme Therapeutics Announces Upsize And Pricing Of Private Offering Of $625 Mln Of Convertible Senior Notes Due 2028
8/15/2022 7:09:05 AM Halozyme Therapeutics Intends To Offer $500 Mln Of Convertible Senior Notes Due 2028
8/2/2022 1:28:45 AM Roche's Phase III IMscin001 Study Of SC Formulation Of Tecentriq With Halozyme's ENHANZE Technology Meets Goals
7/26/2022 11:01:19 PM Halo Announces Termination Of Letter Of Intent With PhytoCann
6/23/2022 7:25:14 AM Concerned Shareholders Of Akanda Corp. Replace Majority Of Akanda's Board Of Directors
6/20/2022 8:59:59 PM Halo Collective Announces Share Consolidation
5/24/2022 8:33:37 AM Halozyme Therapeutics Completes Antares Pharma Acquisition
5/12/2022 8:06:28 AM Halozyme - Antares Pharma Deal Receives U.S. Antitrust Approval
4/28/2022 9:21:31 AM Halo Collective Signs LoI To Acquire Phytocann Group
4/28/2022 2:34:34 AM Halo Collective Acquires Dissolve Medical
4/13/2022 6:07:39 AM Halozyme To Buy Antares For $5.60/shr Cash
3/24/2022 8:09:42 AM Halozyme Therapeutics And Chugai Pharma Enter Collaboration And License Agreement For ENHANZE Technology
3/22/2022 2:27:21 AM Halozyme Therapeutics Says Phase 3 ADAPT-SC Study Meets Primary Endpoint